Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
Mol Pharm
; 21(5): 2065-2080, 2024 May 06.
Article
in En
| MEDLINE
| ID: mdl-38600804
ABSTRACT
Physiologically based biopharmaceutics modeling (PBBM) is used to elevate drug product quality by providing a more accurate and holistic understanding of how drugs interact with the human body. These models are based on the integration of physiological, pharmacological, and pharmaceutical data to simulate and predict drug behavior in vivo. Effective utilization of PBBM requires a consistent approach to model development, verification, validation, and application. Currently, only one country has a draft guidance document for PBBM, whereas other major regulatory authorities have had limited experience with the review of PBBM. To address this gap, industry submitted confidential PBBM case studies to be reviewed by the regulatory agencies; software companies committed to training. PBBM cases were independently and collaboratively discussed by regulators, and academic colleagues participated in some of the discussions. Successful bioequivalence "safe space" industry case examples are also presented. Overall, six regulatory agencies were involved in the case study exercises, including ANVISA, FDA, Health Canada, MHRA, PMDA, and EMA (experts from Belgium, Germany, Norway, Portugal, Spain, and Sweden), and we believe this is the first time such a collaboration has taken place. The outcomes were presented at this workshop, together with a participant survey on the utility and experience with PBBM submissions, to discuss the best scientific practices for developing, validating, and applying PBBMs. The PBBM case studies enabled industry to receive constructive feedback from global regulators and highlighted clear direction for future PBBM submissions for regulatory consideration.
Key words
MIDD (model informed drug development); PBBM (physiologically based biopharmaceutics model(s)(ing); PBPK (physiologically based pharmacokinetics); biopredictive dissolution; clinically relevant dissolution specifications (CRDS); drug product performance; drug product quality; patient-centric drug product quality standards; safe space; virtual bioequivalence (VBE)
Full text:
1
Database:
MEDLINE
Main subject:
Biopharmaceutics
/
Drug Industry
Country/Region as subject:
America do norte
Language:
En
Journal:
Mol Pharm
Year:
2024
Type:
Article
Affiliation country:
Belgium